Thank you for your interest in participating in the BeAT-HF Clinical Trial by CVRx Inc.
The BeAT-HF Clinical Trial is evaluating the investigational BAROSTIM NEO implantable device, designed to electrically stimulate the baroreceptors located on one of the carotid arteries in your neck. This may result in improved heart function and reduced heart failure symptoms. This device is not a defibrillator or a pacemaker, it is a different technology. People implanted with a defibrillator and/or a pacemaker may be potential candidates for the Trial and may use these devices simultaneously.
By answering the questionnaire below we will be able to let you know whether you are likely to be a potential candidate to participate in the BeAT-HF Clinical Trial.
IMPORTANT FACTS: The BeAT Heart Failure Clinical Trial has been approved by the FDA and designated as an Expedited Access Pathway (EAP) program due to its potential as a therapy to treat a life-threatening disease that remains debilitating despite being treated with existing treatments.